Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Retrospective, Non-interventional Study to Evaluate EGFR-Tyrosine Kinase Inhibitor Retreatment in Patients With Locally Advanced or Metastatic EGFR Mutated NSCLC Who Previously Treated With EGFR-TKI as First-line Therapy and Chemotherapy as Second-line Therapy - SEQUENCE Study

NCT01955681 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01955681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01955681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Retrospective, Non-interventional Study to Evaluate EGFR-Tyrosine Kinase Inhibitor Retreatment in Patients With Locally Advanced or Metastatic EGFR Mutated NSCLC Who Previously Treated With EGFR-TKI as First-line Therapy and Chemotherapy as Second-line Therapy - SEQUENCE Study
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
December 31, 2013
Completion date
August 31, 2014
Enrollment
200 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic egfr mutated nsclc.